haloperidol has been researched along with Obsessive-Compulsive Disorder in 50 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nine patients with trichotillomania were treated with haloperidol." | 9.09 | The potential role of haloperidol in the treatment of trichotillomania. ( Farvolden, P; Mancini, C; Oakman, JM; Van Ameringen, M, 1999) |
| "To determine the efficacy of adding haloperidol to the treatment of patients with obsessive-compulsive disorder (OCD), with or without a comorbid chronic tic disorder, who were refractory to adequate treatment with the serotonin-uptake inhibitor fluvoxamine alone." | 9.07 | Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. ( Goodman, WK; Heninger, GR; Leckman, JF; Lee, NC; McDougle, CJ; Price, LH, 1994) |
| " In the present study, we examined the effect of perospirone on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), compared with the effects of other antipsychotics such as haloperidol and risperidone." | 7.73 | Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. ( Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R, 2005) |
| "Erythrocyte and plasma choline parameters were compared in children (n = 63), aged 6-18 years, suffering from Tourette Syndrome (TS), their parents (n = 57), their unaffected siblings (n = 38), and an adult control group (n = 57)." | 7.68 | Controlled study of erythrocyte choline in Tourette syndrome. ( Hanin, I; Kopp, U; Sallee, FR, 1992) |
| "Nine patients with trichotillomania were treated with haloperidol." | 5.09 | The potential role of haloperidol in the treatment of trichotillomania. ( Farvolden, P; Mancini, C; Oakman, JM; Van Ameringen, M, 1999) |
| "To determine the efficacy of adding haloperidol to the treatment of patients with obsessive-compulsive disorder (OCD), with or without a comorbid chronic tic disorder, who were refractory to adequate treatment with the serotonin-uptake inhibitor fluvoxamine alone." | 5.07 | Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. ( Goodman, WK; Heninger, GR; Leckman, JF; Lee, NC; McDougle, CJ; Price, LH, 1994) |
| " In the present study, we examined the effect of perospirone on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), compared with the effects of other antipsychotics such as haloperidol and risperidone." | 3.73 | Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. ( Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R, 2005) |
| "Erythrocyte and plasma choline parameters were compared in children (n = 63), aged 6-18 years, suffering from Tourette Syndrome (TS), their parents (n = 57), their unaffected siblings (n = 38), and an adult control group (n = 57)." | 3.68 | Controlled study of erythrocyte choline in Tourette syndrome. ( Hanin, I; Kopp, U; Sallee, FR, 1992) |
| "Clomipramine hydrochloride, a tricyclic antidepressant that blocks serotonin and norepinephrine reuptake, is indicated in the treatment of Obsessive-Compulsive Disorder." | 3.68 | Tourette's syndrome and treatment with clomipramine hydrochloride. ( Donahoe, DH; Fortune, T; Llorena, R; Meador, M, 1991) |
| "Children with Sydenham's chorea and PANDAS (Pediatric autoimmune neuropsychiatric disorders associated with streptococcal throat infections) share an array of neuropsychiatric symptoms and distinguishing one from the other, especially at onset can prove challenging." | 2.42 | Distinguishing PANDAS from Sydenham's chorea: case report and review of the literature. ( Schoeman, JF; van Toorn, R; Weyers, HH, 2004) |
| "The increasing recognition of Tourette's syndrome is probably responsible for the broadening range of symptom severities seen in clinic patients." | 2.39 | Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. ( Peterson, BS, 1996) |
| "Sydenham's chorea is a symptom of rheumatic fever and results from an autoimmune attack on the CNS." | 2.39 | Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review. ( Moore, DP, 1996) |
| "fluoxetine) anxiolytics inhibit marble burying." | 1.33 | A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. ( Kolb, Y; Nicolas, LB; Prinssen, EP, 2006) |
| "A clear double dissociation of Wisconsin Card Sorting Test and Gambling Task performances was found, with SKZ patients performing the Wisconsin Card Sorting test significantly worse than OCD patients and control subjects and OCD patients performing the Gambling Task significantly worse than SKZ and control subjects." | 1.32 | Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study. ( Angelone, SM; Bassi, T; Bellodi, L; Cavallaro, R; Cavedini, P; Mistretta, P; Ubbiali, A, 2003) |
| " Chronic administration of the selective serotonin re-uptake inhibitors fluoxetine and clomipramine (CMI) at 5 mg/kg per day and fluvoxamine at 10 mg/kg twice a day significantly decreased schedule-induced polydipsia (SIP) on day 15 and throughout the remainder of the study compared to control rats." | 1.29 | Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. ( Corbett, R; Cornfeldt, M; Dunn, RW; Smith, C; Szewczak, M; Woods, A, 1993) |
| " Patients were treated with risperidone in two different dosage groups (3 mg and 8 mg) and haloperidol (10-20 mg) and compared with eight healthy control subjects." | 1.29 | Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. ( Asenbaum, S; Brücke, T; Gössler, R; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J; Topitz-Schratzberger, A; Vesely, C, 1996) |
| "When treated with clomipramine 100 mg daily (plasma level 85 ng/mL), obsessive-compulsive symptoms but not the hallucinations improved significantly, and racing thoughts and grandiosity developed later." | 1.29 | Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. ( Dryden-Edwards, RC; Reiss, AL, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (26.00) | 18.7374 |
| 1990's | 20 (40.00) | 18.2507 |
| 2000's | 9 (18.00) | 29.6817 |
| 2010's | 7 (14.00) | 24.3611 |
| 2020's | 1 (2.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghanbarzehi, A | 1 |
| Sepehrinezhad, A | 1 |
| Hashemi, N | 1 |
| Karimi, M | 1 |
| Shahbazi, A | 1 |
| Rask, O | 1 |
| Suneson, K | 1 |
| Holmström, E | 1 |
| Bäckström, B | 1 |
| Johansson, BA | 1 |
| Arikawa, A | 1 |
| Mito, H | 1 |
| Motoyama, M | 1 |
| Yamanishi, K | 1 |
| Hayashida, K | 1 |
| Maebayashi, K | 1 |
| Matsunaga, H | 1 |
| Danovich, L | 1 |
| Weinreb, O | 1 |
| Youdim, MB | 1 |
| Silver, H | 1 |
| Nakamae, T | 1 |
| Ulhaq, I | 1 |
| Abba-Aji, A | 1 |
| Schmidt, TT | 1 |
| Rea, E | 1 |
| Shababi-Klein, J | 1 |
| Panagis, G | 1 |
| Winter, C | 1 |
| Kreiss, DS | 1 |
| Coffman, CF | 1 |
| Fiacco, NR | 1 |
| Granger, JC | 1 |
| Helton, BM | 1 |
| Jackson, JC | 1 |
| Kim, LV | 1 |
| Mistry, RS | 1 |
| Mizer, TM | 1 |
| Palmer, LV | 1 |
| Vacca, JA | 1 |
| Winkler, SS | 1 |
| Zimmer, BA | 1 |
| Joel, D | 1 |
| Doljansky, J | 1 |
| Cavallaro, R | 1 |
| Cavedini, P | 1 |
| Mistretta, P | 1 |
| Bassi, T | 1 |
| Angelone, SM | 1 |
| Ubbiali, A | 1 |
| Bellodi, L | 1 |
| SVENDSEN, BB | 1 |
| WILLADSEN, J | 1 |
| Kano, Y | 1 |
| van Toorn, R | 1 |
| Weyers, HH | 1 |
| Schoeman, JF | 1 |
| Li, X | 1 |
| May, RS | 1 |
| Tolbert, LC | 1 |
| Jackson, WT | 1 |
| Flournoy, JM | 1 |
| Baxter, LR | 1 |
| Machida, N | 1 |
| Shiotsuka, S | 1 |
| Semba, J | 1 |
| Matsushita, M | 1 |
| Egashira, N | 1 |
| Harada, S | 1 |
| Okuno, R | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Nishimura, R | 1 |
| Fujiwara, M | 1 |
| Bloch, MH | 1 |
| Landeros-Weisenberger, A | 1 |
| Kelmendi, B | 1 |
| Coric, V | 1 |
| Bracken, MB | 1 |
| Leckman, JF | 3 |
| Nicolas, LB | 1 |
| Kolb, Y | 1 |
| Prinssen, EP | 1 |
| Cohen, DJ | 1 |
| McDougle, CJ | 3 |
| Goodman, WK | 3 |
| Price, LH | 2 |
| Woods, A | 1 |
| Smith, C | 1 |
| Szewczak, M | 1 |
| Dunn, RW | 1 |
| Cornfeldt, M | 1 |
| Corbett, R | 1 |
| Budman, CL | 1 |
| Sherling, M | 1 |
| Bruun, RD | 1 |
| LaPorta, LD | 1 |
| Lee, NC | 1 |
| Heninger, GR | 1 |
| Escobar, R | 1 |
| Bernardo, M | 1 |
| Rickards, H | 1 |
| Peterson, BS | 1 |
| Küfferle, B | 1 |
| Brücke, T | 1 |
| Topitz-Schratzberger, A | 1 |
| Tauscher, J | 1 |
| Gössler, R | 1 |
| Vesely, C | 1 |
| Asenbaum, S | 1 |
| Podreka, I | 1 |
| Kasper, S | 1 |
| Dryden-Edwards, RC | 1 |
| Reiss, AL | 1 |
| Leonard, HL | 1 |
| Moore, DP | 1 |
| Benazzi, F | 1 |
| Van Ameringen, M | 1 |
| Mancini, C | 1 |
| Oakman, JM | 1 |
| Farvolden, P | 1 |
| Gelenberg, AJ | 1 |
| Mandel, MR | 1 |
| Sallee, FR | 1 |
| Kopp, U | 1 |
| Hanin, I | 1 |
| Stárková, L | 2 |
| Wiedermann, J | 1 |
| Donahoe, DH | 1 |
| Meador, M | 1 |
| Fortune, T | 1 |
| Llorena, R | 1 |
| Matthews, P | 1 |
| Quinn, D | 1 |
| Marcoux, GS | 1 |
| Falkenberg, K | 1 |
| Mrna, B | 1 |
| Caine, ED | 1 |
| McBride, MC | 1 |
| Chiverton, P | 1 |
| Bamford, KA | 1 |
| Rediess, S | 1 |
| Shiao, J | 1 |
| Ananth, J | 1 |
| Baer, L | 1 |
| Minichiello, WE | 1 |
| Jenike, MA | 1 |
| Carman, JS | 1 |
| Woodrow, KM | 1 |
| O'Regan, JB | 2 |
| Hussain, MZ | 1 |
| Ahad, A | 1 |
| Greger, J | 1 |
| Glitschka, A | 1 |
| Müller, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564] | Phase 4 | 21 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study[NCT04978428] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-04-14 | Recruiting | ||
| Open Label Study for the Use of Transcranial Ultrasound Treatment of Obsessive-Compulsive Disorder[NCT04775875] | 30 participants (Anticipated) | Interventional | 2020-12-01 | Enrolling by invitation | |||
| [NCT00004325] | 200 participants | Observational | 1988-12-31 | Completed | |||
| Initial Evaluation of Efficacy and Adverse Events of Single Lesions in Bilateral Ventral-capsular and Ventral Capsulotomy-striatal by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder[NCT02500888] | 10 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
14 reviews available for haloperidol and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
[Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
Topics: Antipsychotic Agents; Autistic Disorder; Body Dysmorphic Disorders; Clomipramine; Comorbidity; Disru | 2011 |
[Chronic tic disorders--chronic mortor or vocal tic disorders and de la Tourette's syndrome].
Topics: Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2003 |
Distinguishing PANDAS from Sydenham's chorea: case report and review of the literature.
Topics: Child; Chorea; Diagnosis, Differential; Haloperidol; Humans; Long-Term Care; Male; Neurologic Examin | 2004 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
Recent advances in Gilles de la Tourette syndrome: implications for clinical practice and future research.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Compulsive | 1983 |
Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Clomipramine; Clozapine; Dopamine Antagonists | 1994 |
Tics and fits. The current status of Gilles de la Tourette syndrome and its relationship with epilepsy.
Topics: Antipsychotic Agents; Diagnosis, Differential; Epilepsies, Partial; Haloperidol; Humans; Obsessive-C | 1995 |
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Child; Clozapine; Disease Progression; Diseas | 1996 |
Update on pharmacologic management of OCD: agents and augmentation.
Topics: Clinical Trials as Topic; Clozapine; Dopamine Agents; Drug Therapy, Combination; Female; Fenfluramin | 1997 |
New developments in the treatment of obsessive-compulsive disorder.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Age Factors; Age of Onset; Antidepressive Agents, Second- | 1997 |
Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review.
Topics: Adult; Autoimmune Diseases; Chorea; Comorbidity; Haloperidol; Humans; Mental Disorders; Obsessive-Co | 1996 |
Obsessive-compulsive disorder: diagnosis and treatment.
Topics: Anxiety Disorders; Behavior Therapy; Clinical Trials as Topic; Combined Modality Therapy; Comorbidit | 1999 |
Clomipramine: an antiobsessive drug.
Topics: Anxiety; Behavior Therapy; Clinical Trials as Topic; Clomipramine; Compulsive Behavior; Depressive D | 1986 |
Gilles de la Tourette's disease--a review.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Corpus Striatum; Diagnosis, Differential; Female; | 1974 |
4 trials available for haloperidol and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Drug Ther | 2005 |
Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
Topics: Adolescent; Adult; Age of Onset; Behavior Therapy; Comorbidity; Double-Blind Method; Drug Therapy, C | 1994 |
The potential role of haloperidol in the treatment of trichotillomania.
Topics: Adult; Anti-Dyskinesia Agents; Female; Haloperidol; Humans; Male; Middle Aged; Obsessive-Compulsive | 1999 |
Clomipramine: an antiobsessive drug.
Topics: Anxiety; Behavior Therapy; Clinical Trials as Topic; Clomipramine; Compulsive Behavior; Depressive D | 1986 |
33 other studies available for haloperidol and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Disclosing common biological signatures and predicting new therapeutic targets in schizophrenia and obsessive-compulsive disorder by integrated bioinformatics analysis.
Topics: Haloperidol; Humans; MicroRNAs; Obsessive-Compulsive Disorder; Psychotic Disorders; Schizophrenia; S | 2023 |
Electroconvulsive therapy for manic state with mixed and psychotic features in a teenager with bipolar disorder and comorbid episodic obsessive-compulsive disorder: a case report.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Electroconvulsive | 2017 |
[A Case with Multiple Comorbidities of Obsessive-Compulsive and Related Disorders].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Dysmorphic Disorders; Clonazepam; Combined Modality | 2015 |
The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Cells, Cultured; Clozapine; Dopamine; Drug The | 2011 |
Haloperidol induced obsessive compulsive symptom (OCS) in a patient with learning disability and bipolar affective disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Diagnosis, Differential; Haloperidol; Humans; Learnin | 2012 |
Enhanced reward-facilitating effects of d-amphetamine in rats in the quinpirole model of obsessive-compulsive disorder.
Topics: Analysis of Variance; Animals; Central Nervous System Stimulants; Conditioning, Operant; Dextroamphe | 2013 |
Ritualistic chewing behavior induced by mCPP in the rat is an animal model of obsessive compulsive disorder.
Topics: Animals; Behavior, Animal; Clomipramine; Diazepam; Disease Models, Animal; Dopamine Antagonists; Flu | 2013 |
Selective alleviation of compulsive lever-pressing in rats by D1, but not D2, blockade: possible implications for the involvement of D1 receptors in obsessive-compulsive disorder.
Topics: Animals; Benzazepines; Compulsive Behavior; Conditioning, Operant; Cues; Dopamine Antagonists; Dopam | 2003 |
Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Case-Control Studies; Clozapine; Corpus Striatum; Dissoc | 2003 |
THE USE OF HALOPERIDOL (SERENASE (R)) IN CHLORPROTIXEN RESISTANT PATIENTS.
Topics: Accommodation, Ocular; Adolescent; Antisocial Personality Disorder; Bipolar Disorder; Chlorprothixen | 1963 |
[Case of obsessive-compulsive disorder associated with neuroleptics-induced deficit syndrome (NIDS): successfully treated by discontinuation of neuroleptics followed by SSRI].
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Fluvoxamine; Haloperidol; Human | 2005 |
Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Mod | 2005 |
A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Diazepa | 2006 |
Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder.
Topics: Animals; Clomipramine; Conditioning, Operant; Desipramine; Diazepam; Disease Models, Animal; Drinkin | 1993 |
Combined pharmacotherapy risk.
Topics: Child; Drug Therapy, Combination; Haloperidol; Humans; Male; Obsessive-Compulsive Disorder; Paroxeti | 1995 |
More on obsessive-compulsive symptoms and clozapine.
Topics: Adult; Clozapine; Haloperidol; Humans; Male; Obsessive-Compulsive Disorder; Schizophrenia; Schizophr | 1994 |
Schizophrenia, obsessive-compulsive disorder, and Tourette's syndrome: a case of triple comorbidity.
Topics: Adult; Basal Ganglia Diseases; Brain; Clomipramine; Comorbidity; Female; Haloperidol; Humans; Obsess | 1993 |
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzamides; Brain Mapping; Dopamin | 1996 |
Differential response of psychotic and obsessive symptoms to risperidone in an adolescent.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Antipsychotic Agents; Clomipramine; Hallucinatio | 1996 |
Urinary retention with sertraline, haloperidol, and clonazepam combination.
Topics: Adult; Antipsychotic Agents; Clonazepam; Comorbidity; Constipation; Delusions; Drug Therapy, Combina | 1998 |
Catatonic reactions to high-potency neuroleptic drugs.
Topics: Adolescent; Adult; Amantadine; Catatonia; Dose-Response Relationship, Drug; Female; Fluphenazine; Ha | 1977 |
Controlled study of erythrocyte choline in Tourette syndrome.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Choline; Drug Therapy, Combination | 1992 |
Our experience with incisive neuroleptic drugs in child psychiatry.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Haloperidol; Humans; Mental Disorders; Obsessive-Com | 1991 |
Tourette's syndrome and treatment with clomipramine hydrochloride.
Topics: Adult; Clomipramine; Drug Administration Schedule; Haloperidol; Humans; Male; Obsessive-Compulsive D | 1991 |
Fluoxetine and neuroleptic synergistic effects.
Topics: Adolescent; Chlorpromazine; Diseases in Twins; Drug Synergism; Fluoxetine; Haloperidol; Humans; Male | 1991 |
Incisive neuroleptic drugs in child psychiatry.
Topics: Antipsychotic Agents; Child; Child Psychiatry; Haloperidol; Humans; Obsessive-Compulsive Disorder; P | 1989 |
Tourette's syndrome in Monroe County school children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Child, Preschool; Clonid | 1988 |
Behavioral treatment in two cases of obsessive-compulsive disorder with concomitant bipolar affective disorder.
Topics: Adult; Behavior Therapy; Bipolar Disorder; Desipramine; Female; Haloperidol; Humans; Lithium; Male; | 1985 |
Hyperdopaminergic states: a continuum.
Topics: Dihydroxyphenylalanine; Haloperidol; Humans; Obsessive-Compulsive Disorder; Physostigmine; Tryptopha | 1972 |
Treatment of obsessive-compulsive neurosis.
Topics: Haloperidol; Humans; Obsessive-Compulsive Disorder; Tourette Syndrome | 1970 |
Treatment of obsessive--compulsive neurosis with haloperidol.
Topics: Haloperidol; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder | 1970 |
Treatment of obsessive-compulsive neurosis.
Topics: Amitriptyline; Chlordiazepoxide; Chlorprothixene; Haloperidol; Humans; Imipramine; Obsessive-Compuls | 1970 |
[On the position of the butyrophenone derivative Haloperidol in psychiatric treatment].
Topics: Adult; Aged; Bipolar Disorder; Catatonia; Child; Depression; Depressive Disorder, Major; Extrapyrami | 1968 |